Timing of administration of bevacizumab chemotherapy affects wound healing after chest wall port placement
Open Access
Abstract
BACKGROUND: The authors investigated how the timing of administration of bevacizumab, a targeted vascular endothelial growth factor‐inhibiting chemotherapeutic agent, affected the risk of wound healing in patients undergoing chest wall port placement.METHODS: The authors performed a retrospective search was performed of an institutional review board approved, Health Insurance Portability and Accountability Act compliant database between 2002 and 2008, identifying 1108 port placements in patients who were treated with bevacizumab. One hundred twenty of these ports eventually required explant. Data analyzed included patient demographics, indication for port removal, and schedule of bevacizumab therapy.RESULTS: Wound healing complications requiring port explant were seen in 0.9% of placements (10/1108). When bevacizumab was given within 1 day of port placement, the absolute risk (AR) of port removal for wound dehiscence was 2.4% (2/82), compared with 0.3% (3/1021) when 2 or more days had passed between port placement and bevacizumab administration, yielding a statistically significant relative risk (RR) of 8.1 (P < .02). Similarly, when bevacizumab was administered within 7 days of port insertion, there was a significant RR of dehiscence‐related port explant (AR 1.4% vs 0.1%, RR 11.5, P < .028). However, no significant RR for dehiscence‐related port removal was observed when bevacizumab was administered within 14 days (AR 0.9% vs 0.2%, RR 6.2, P < .09) or 30 days (AR 0.7% vs 0.2%, RR 3.7, P < .23) of port placement.CONCLUSIONS: The risk of a wound dehiscence requiring chest wall port explant in patients treated with bevacizumab was inversely proportional to the interval between bevacizumab administration and port placement, with significantly higher risk seen when the interval is less than 14 days. Cancer 2011. © 2010 American Cancer Society.Keywords
This publication has 30 references indexed in Scilit:
- Bevacizumab: current indications and future development for management of solid tumorsExpert Opinion on Biological Therapy, 2009
- Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast CancerNew England Journal of Medicine, 2007
- VEGF in biological controlJournal of Cellular Biochemistry, 2007
- Angiogenesis inhibition with bevacizumab and the surgical management of colorectal cancerBritish Journal of Surgery, 2006
- Incidence and management of bevacizumab-related toxicities in colorectal cancerExpert Opinion on Drug Safety, 2006
- Endothelial cells and VEGF in vascular developmentNature, 2005
- VEGF and the quest for tumour angiogenesis factorsNature Reviews Cancer, 2002
- Vascular Permeability Factor/Vascular Endothelial Growth Factor: An Important Mediator of Angiogenesis in Malignancy and InflammationInternational Archives of Allergy and Immunology, 1995
- Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivoNature, 1993
- Statistics in Medicine: Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and ratesBMJ, 1988